Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine for IOP Control During Pupil Dilation
NCT03959176Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of brimonidine tartrate + sodium hyaluronate in ocular hypertension, sponsored by Wake Forest University Health Sciences. Primary endpoint: Intraocular Pressure at 4 hours. Started Jul 2019; status: completed.
02
Drugs
brimonidine tartrate + sodium hyaluronate
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT03959176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959176.